Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5184839
Max Phase: Preclinical
Molecular Formula: C23H25F2N3O4
Molecular Weight: 445.47
Associated Items:
ID: ALA5184839
Max Phase: Preclinical
Molecular Formula: C23H25F2N3O4
Molecular Weight: 445.47
Associated Items:
Canonical SMILES: O=C(CN(Cc1ccc(C(=O)NO)cc1F)C(=O)c1ccccc1F)NC1CCCCC1
Standard InChI: InChI=1S/C23H25F2N3O4/c24-19-9-5-4-8-18(19)23(31)28(14-21(29)26-17-6-2-1-3-7-17)13-16-11-10-15(12-20(16)25)22(30)27-32/h4-5,8-12,17,32H,1-3,6-7,13-14H2,(H,26,29)(H,27,30)
Standard InChI Key: JQJAILQGBYOWRZ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 445.47 | Molecular Weight (Monoisotopic): 445.1813 | AlogP: 3.18 | #Rotatable Bonds: 7 |
Polar Surface Area: 98.74 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.96 | CX Basic pKa: | CX LogP: 2.82 | CX LogD: 2.81 |
Aromatic Rings: 2 | Heavy Atoms: 32 | QED Weighted: 0.45 | Np Likeness Score: -1.75 |
1. Reßing N, Schliehe-Diecks J, Watson PR, Sönnichsen M, Cragin AD, Schöler A, Yang J, Schäker-Hübner L, Borkhardt A, Christianson DW, Bhatia S, Hansen FK.. (2022) Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia., 65 (22.0): [PMID:36351184] [10.1021/acs.jmedchem.2c01418] |
Source(1):